B+
Bull case
25%
Probability
Target price
$46.00
+39.1% vs current
TEVA
Teva Pharmaceutical IndustriesANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$40.00
+20.9% vs current
B-
Bear case
25%
Probability
Target price
$29.00
-12.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+66.2
Score
AI commentary
Primary-source evidence is constructive: Q1 results were strong, the outlook was maintained, and the Emalex and olanzapine milestones create dated catalysts. The packet has no fresh analyst revision set, so this remains a cautious monitoring view rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-29eventQ1 2026 results reinforce the growth-pivot thesisMedium impact
Teva's April 29 press release said Q1 2026 revenue was about $4.0 billion and that strong growth in AUSTEDO, AJOVY, and UZEDY, plus disciplined execution, drove the quarter; the company also kept its 2026 outlook intact. [#8-K-2026-04-29]
2026-09-30eventEmalex closing could add a pipeline uplift but tests margin disciplineMedium impact
Teva said the Emalex Biosciences acquisition is subject to customary regulatory approvals, is currently anticipated to close by Q3 2026, will be funded with cash on hand, and may be margin dilutive near term even as management said it remains on track for 2027 financial targets. [#8-K-2026-04-29]
2026-12-31catalystOlanzapine LAI stays a second-half 2026 launch candidateMedium impact
Teva's 10-Q and April release keep olanzapine LAI in the pipeline as an FDA-accepted NDA with an EMA application still pending, preserving a Q4 2026 launch catalyst if approvals land on schedule. [#10-Q-2026-04-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology